A5044330795- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Otitis Media and Relapsing Polychondritis
- T-cell and B-cell Immunology
- Systemic Sclerosis and Related Diseases
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Herpesvirus Infections and Treatments
- Cancer Diagnosis and Treatment
- Celiac Disease Research and Management
- Helicobacter pylori-related gastroenterology studies
- Renal Diseases and Glomerulopathies
- Inflammatory Bowel Disease
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Lymphoma Diagnosis and Treatment
- Autoimmune Bullous Skin Diseases
- Cytomegalovirus and herpesvirus research
- Cassava research and cyanide
- Pharmacological Effects of Natural Compounds
- Cutaneous lymphoproliferative disorders research
- Inflammasome and immune disorders
- Chronic Lymphocytic Leukemia Research
- Peripheral Neuropathies and Disorders
University of Crete
2022-2025
University Hospital of Heraklion
2020-2023
Center for Rheumatology
2023
The General Hospital of Heraklion "Venizeleio-Pananio"
2018
Background Characterisation of the long-term outcome patients with ‘difficult to treat’ (D2T) rheumatoid arthritis and factors contributing its evolution are unknown. Herein, we explored heterogeneity D2T outcome. Methods Patients included from a prospective single centre cohort study. The EULAR definition was applied. Longitudinal clustering functional status (modified Health Assessment Questionnaire (mHAQ)) disease activity (Disease Activity Score-28 (DAS28)) were assessed using...
Objectives Treatment targets in systemic lupus erythematosus (SLE) have been validated unselected—in terms of severity—cohorts, which limits their generalisability. We assessed remission (Definition Remission SLE (DORIS)) and Lupus Low Disease Activity State (LLDAS) a historical cohort 348 patients with active moderate-to-severe disease median follow-up 5 years. Methods Active was defined as Physician Global Assessment ≥1.5 and/or Index 2000 ≥6, requiring therapy intensification....
Glucocorticoid (GC) tapering and withdrawal to reduce damage represents a key aspect of the European Alliance Associations for Rheumatology (EULAR) SLE recommendations. However, optimal strategies relapse-free GC cessation remain ill-defined. We characterised clinical predictors their combined effect on flares in patients with who discontinued GC. Retrospective cohort 324 active (PGA ≥1.5 and/or SLEDAI-2K ≥6) received as part treatment intensification (median follow-up 60 months). Survival...
Objective To obtain real-world data on outcomes of belimumab treatment and respective prognostic factors in patients with systemic lupus erythematosus (SLE). Methods Observational study 188 active SLE (median disease duration 6.2 years, two previous immunosuppressive/biological agents) treated belimumab, who were monitored for SLEDAI-2K, Physician Global Assessment (PGA), LLDAS (lupus low activity state), remission (DORIS/Padua definitions), SELENA-SLEDAI Flare Index, SLICC/ACR damage index...
Persistent hiccups can be a debilitating symptom and many such patients present to the emergency department seeking relief. A variety of serious conditions have been associated with persistent hiccups. Cases pneumonia as cause rarely described.A 79-year-old male patient presented hospital due for 4 days. Despite lack new respiratory symptoms or fever, chest x-ray demonstrated left lower lobe consolidation, which was also confirmed CT. The treated levofloxacin at 1-month follow-up had...
abdominal pain as first clinical symptom may erroneously lead to the diagnosis of acute abdomen and unnecessary exploratory laparotomy, 2 posing a significant risk for delayed treatment unfavorable outcome.In addition, few cases have reported perivascular fat stranding on computed tomography (CT) in setting visceral HZ. 3,4 This report details rare case HZ with but no skin
Mental disorders such as anxiety and depression are prevalent in systemic lupus erythematosus (SLE) patients, yet their association with the underlying disease activity remains uncertain has been mostly evaluated at a cross-sectional level. To examine longitudinal trends anxiety, depression, activity, prospective observational study was performed on 40 adult SLE outpatients active (SLE Disease Activity Index [SLEDAI]-2K ≥ 3 [excluding serology]) who received standard-of-care. Anxiety were...
<h3>Objective</h3> We assessed the attainment of remission (DORIS) and lupus low disease activity state (LLDAS) in patients with active moderate-to-severe minimum time dependent exposure associated to lower risk for organ damage accrual severe flares. Thus far, feasibility these targets has been validated particularly unselected SLE cohorts observational studies, posing a question their difficult treat patients. <h3>Methods</h3> This is retrospective cohort study aged ≥16 years who fulfilled...
<h3>Background:</h3> Data regarding the adoption of treat-to-target (T2T) approach aiming at inactive disease (ID), or low activity (LDA) in axial (axSpA) and peripheral Spondyloarthritis (perSpA) real-world clinical practice is scarce. <h3>Objectives:</h3> Our aims were to assess level SpA patients practice, extent T2T strategy implementation reasons possible non-implementation. <h3>Methods:</h3> Cross-sectional study all consecutive with who visited outpatient department one-day infusions'...
Background . IgA glomerulonephritis may present with hematuria, flank pain, and fever. This clinical presentation be easily confused acute pyelonephritis. Case Report We the case of a 25-year-old female typical for pyelonephritis (high fever, left costovertebral angle tenderness, elevated inflammatory markers, hypoenhancing region in kidney on contrast-enhanced computed tomography). However, urine blood cultures were both negative, serum creatinine was elevated, urinalysis revealed...
Background: Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disorder. In recent years biological modifying antirheumatic drugs (bDMARDs) are becoming increasingly important for its treatment. Objectives: To evaluate outcomes, treatment strategies and their long-term safety in cohort of AOSD patients treated with bDMARDs. Methods: A single-center retrospective study diagnosed until 2019 was conducted. Patients were included if they: a) 16 old or older, b) met the Yamaguchi...
Background Mental disorders such as anxiety and depression are highly prevalent in SLE patients,[1] yet their association with the underlying disease activity remains elusive has been mostly evaluated at cross-sectional level.[2] This is further complicated by often-increased rates of treatment non-adherence,[3] an important determinant heightened lupus activity, among patients depression.[4] Objectives To examine relationship between longitudinal changes (ICD-10-CM F41.9), F32.x) levels...
Abstract To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). Prospective observational study of RA, axial (AxSpA) peripheral SpA (PerSpA) etanercept during 2004–2020. Kaplan–Meier plots were used for comparisons multivariable Cox regression models predictors discontinuation. Long-term identified by latent class growth using DAS28-ESR...
New biologic and small molecule targeted agents have expanded the armamentarium of Spondyloarthritides (SpA), allowing more therapeutic options for patients who do not respond to therapy.The implementation treat-to-target (T2T) strategy with close monitoring frequent treatment adaptations targeting disease remission has been proposed as means prevent radiographic progression long-term adverse outcomes.In this project we will employ "University Crete Rheumatology Clinic Registry"...
Background Belimumab has been introduced in the management of SLE for more than 10 years, however long-term efficacy and safety data are still limited mostly derive from extended phase randomized clinical trials. Objectives To evaluate survival belimumab treatment, reasons treatment cessation associated predictors routine care setting. Methods Multicentre observational study adult patients who were treated with according to physician discretion line EULAR recommendations. Disease activity...
Background: Herein we aimed to characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) spondylarthritis (SpA) patients on etanercept treatment.Methods: Prospective observational study of RA, axial (AxSpA) peripheral SpA (PerSpA) initiating during 2004-2020. Kaplan-Meier plots were used for comparisons multivariate Cox regression models predictors discontinuation. Long-term identified by latent class growth using DAS28-ESR or ASDAS-CRP as...
Background: Long-term observational studies of patients under biologic disease-modifying anti-rheumatic drug (bDMARD) therapies in routine clinical practice can provide us with important data regarding comorbidities, who are usually excluded from randomized controlled studies. Objectives: To study the impact comorbidities outcome (response and persistence to therapy) spondyloarthritis (SpA) receiving bDMARDs real-world practice. Methods: Prospective all start a bDMARD tertiary centre...
Background: There is limited information on the burden of comorbidities in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) real-world clinical practice its impact incidence serious adverse events (SAE) during biologic disease-modifying anti-rheumatic drug (bDMARD) therapy. Objectives: To evaluate number RA SpA initiating a bDMARD everyday to explore association occurrence SAE Methods: Prospective study all who start any treatment tertiary centre University Hospital. All...
Background: Difficult-to-treat rheumatoid arthritis (D2T RA) was recently defined by a EULAR study group (1) and, as disease category it is largely complicated and under-researched. Patient comorbidities may play significant role in the response to therapy with biologic disease-modifying antirheumatic drugs (bDMARDs) classification D2T RA. Objectives: To evaluate impact of [studied total Comorbidities Count (CC) rheumatic comorbidity index (RDCI)] on 6-month first bDMARD real-world clinical...